https://www.avient.com/products/engineered-polymer-formulations/sustainable-formulations/gravi-tech-lead-replacement-formulations
Explore What's Possible
Explore What’s Possible
https://www.avient.com/products/engineered-polymer-formulations/sustainable-formulations/maxxam-bio-bio-based-polyolefin-formulations
Explore What's Possible
Explore What's Possible
https://www.avient.com/products/engineered-polymer-formulations/sustainable-formulations/maxxam-rec-recycled-polyolefin-formulations
Explore What’s Possible
Explore What's Possible
https://www.avient.com/products/polymer-additives/uv-and-light-blocking-additives/cesa-light-additives
Explore What's Possible
Explore What's Possible
https://www.avient.com/products/polymer-colorants/liquid-color-concentrates/colormatrix-optica-specialty-toners-pc
Explore What's Possible
Explore What's Possible
https://www.avient.com/products/polymer-additives/uv-and-light-blocking-additives/colormatrix-ultimate-uv390-light-barrier-pet
Explore What's Possible
Explore What's Possible
https://www.avient.com/products/polymer-additives/processing-enhancement-additives/colorant-chromatics-pvdf-processing-aids
Explore What's Possible
Explore What's Possible
https://www.avient.com/sites/default/files/resources/GHS%2520MSDS%2520Updates%2520Letter.pdf
What our customers will see:
In mid-April 2014, our newly formulated or significantly reformulated U.S. and European solutions will be
accompanied by a new GHS-formatted MSDS (CLP classification in Europe).
https://www.avient.com/sites/default/files/2020-05/1.-polyone-ir-presenstation-fermium-research-chemicals-conference.pdf
Reconciliation to Adjusted EPS Excluding Special Items and Impacts of February 2020 Equity Offering
Three MonthsEnded
March 31, 2020
Net income from continuing operations – GAAP $ 33.1
Special items, after tax(1) 8.6
After tax interest income earned on equity proceeds, included in Interest expense, net (0.7)
Adjusted net income excluding special items and impact of interest income on equity proceeds $ 41.0
Diluted weighted-average shares used to compute earnings per common share 86.7
Weighted-average impact of 15.3 million shares issued in February 2020 equity offering (9.3)
Diluted weighted-average shares excluding impact of shares issued in February 2020 equity offering 77.4
Adjusted EPS - excluding special items and the net impact of equity offering $ 0.53
Reconciliation of Non-GAAP Financial Measures (Unaudited)
(Dollars in millions, except per share data)
Senior management uses comparisons of adjusted net income from continuing operations attributable to PolyOne shareholders and diluted adjusted earnings per share (EPS) from continuing
operations attributable to PolyOne shareholders, excluding special items, to assess performance and facilitate comparability of results.
https://www.avient.com/sites/default/files/2020-05/2.-polyone-ir-presenstation-wells-fargo-industrials-conference.pdf
Reconciliation to Adjusted EPS Excluding Special Items and Impacts of February 2020 Equity Offering
Three MonthsEnded
March 31, 2020
Net income from continuing operations – GAAP $ 33.1
Special items, after tax(1) 8.6
After tax interest income earned on equity proceeds, included in Interest expense, net (0.7)
Adjusted net income excluding special items and impact of interest income on equity proceeds $ 41.0
Diluted weighted-average shares used to compute earnings per common share 86.7
Weighted-average impact of 15.3 million shares issued in February 2020 equity offering (9.3)
Diluted weighted-average shares excluding impact of shares issued in February 2020 equity offering 77.4
Adjusted EPS - excluding special items and the net impact of equity offering $ 0.53
Reconciliation of Non-GAAP Financial Measures (Unaudited)
(Dollars in millions, except per share data)
Senior management uses comparisons of adjusted net income from continuing operations attributable to PolyOne shareholders and diluted adjusted earnings per share (EPS) from continuing
operations attributable to PolyOne shareholders, excluding special items, to assess performance and facilitate comparability of results.